The EMA's human medicines committee (CHMP) has recommended a conditional marketing authorisation for Veklury (remdesivir) to treat COVID-19.
List view / Grid view
EMA human medicines committee (CHMP)
The EMA has announced new regulatory changes that will help potential COVID-19 vaccines and therapeutics accelerate through development.
The EMA's human medicines committee has announced it has begun a rolling review of remdesivir for the treatment of COVID-19, to examine its safety and effectiveness.
The EMA's human medicines committee has adopted a positive opinion for eight medicines, recommending their marketing authorisation.
A summary of the CHMP meeting conclusions, including medicines recommended for approval and indication extension and several safety review findings.
The EMA has urged that the research community prioritise large randomised controlled studies for COVID-19 treatments and vaccines.
The EMA has recommended granting marketing authorisation to two medicines and extending the indications for three more following its latest meeting.
The EMA CHMP has revealed its suggestion to grant marketing authorisation to seven medicines after its most recent meeting.